慢性鼻窦炎伴鼻息肉生物制剂转换治疗的疗效:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项研究共470例慢性鼻窦炎伴鼻息肉患者,评估生物制剂转换治疗的疗效与安全性。转换最常见原因为鼻窦炎症状控制不足(59.7%),SNOT-22评分平均改善71.4%,转换至度普利尤单抗后SNOT-22与鼻息肉评分均显著改善,转换成功率平均79.2%。
要点
- 生物制剂转换最常见原因为症状控制不足(59.7%),其次为不良反应(10.8%)。
- 转换后SNOT-22评分平均改善71.4%,成功率范围59.6%–100%,平均79.2%。
- 转换至度普利尤单抗者SNOT-22与鼻息肉评分均显著改善。
核心结论
- 生物制剂转换是难治性慢性鼻窦炎伴鼻息肉或出现生物制剂副作用患者的一种治疗选择。
研究设计与样本
- 系统综述与荟萃分析,检索Web of Science、Cochrane、MEDLINE和Embase数据库至2025年6月。
- 共识别3367项研究,最终纳入8项研究(470例患者),其中4项进入荟萃分析。
主要发现
- 转换最常见原因为CRS症状控制不足(59.7%),其次为不良副作用(10.8%)。
- SNOT-22评分平均改善71.4%。
- 转换至度普利尤单抗后SNOT-22和鼻息肉评分均显著改善。
- 生物制剂转换成功率范围为59.6%至100%,平均成功率79.2%。
临床怎么用
- 对难治性CRSwNP或出现生物制剂副作用的患者,可考虑生物制剂转换治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biological therapy is a newer line of treatment that has been utilized in practice for patients with chronic rhinosinusitis with nasal polyps, showing excellent results. However, some patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) do not respond to this therapy. Hence, this study aims to evaluate the efficacy and safety of biological switching in these patients. METHODOLOGY: Using the Web of Science, Cochrane, MEDLINE, and Embase databases, we analyzed studies involving biological switching in CRSwNP patients published up to June 2025. The studies were extracted, and data were pooled for meta-analysis. RESULTS: Of 3,367 studies identified, eight studies (involving 470 patients) were included in the systematic review, four of which were included in the meta-analysis. The results showed that the most common reason for switching was insufficient CRS symptom control (59.7%), followed by undesirable side effects (10.8%). The findings demonstrated dramatic effects of biological switching in terms of the SNOT-22 score, with a mean improvement of 71.4%. In addition, studies that switched patients to dupilumab showed significant improvement after switching in both SNOT-22 and nasal polyp scores. Overall, the success rate of biological switching ranged from 59.6% to 100%, with an average success rate of 79.2%. CONCLUSIONS: This review demonstrated the effect of biological switching as an option for patients with refractory CRSwNP or those experiencing biological side effects. These findings highlight a new therapeutic alternative that can serve as a fundamental choice when managing CRSwNP patients.
引用
- Aljubran HJ, Alabdulaal MR, Aldhaif LA, et al. Therapeutic outcomes of biologic switching in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Rhinology. 2026. PMID: 42334381. doi:10.4193/Rhin25.623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。